NASDAQ:BCRX
BioCryst Pharmaceuticals Stock News
$4.57
+0.440 (+10.65%)
At Close: May 01, 2024
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
10:20am, Wednesday, 18'th May 2022 Zacks Investment Research
Smart Beta ETF report for XBI
BioCryst to Present at Upcoming Investor Conferences
11:00am, Friday, 06'th May 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:
BioCryst to Present at Upcoming Investor Conferences
07:00am, Friday, 06'th May 2022
RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:
Why BioCryst Stock Lost Nearly 4% of Its Value Today
10:10pm, Thursday, 05'th May 2022 The Motley Fool
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
BioCryst Pharmaceuticals (BCRX) Q1 2022 Earnings Call Transcript
07:00pm, Thursday, 05'th May 2022 The Motley Fool
BCRX earnings call for the period ending March 31, 2022.
Why BioCryst Stock Lost Nearly 4% of Its Value Today
06:10pm, Thursday, 05'th May 2022
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates
12:25pm, Thursday, 05'th May 2022 Zacks Investment Research
BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
11:00am, Thursday, 05'th May 2022 GlobeNewswire Inc.
—Q1 2022 ORLADEYO net revenue of $49.7 million—
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:15pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors grant
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
10:20am, Wednesday, 04'th May 2022 Zacks Investment Research
Sector ETF report for XBI
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to Decline
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why BioCryst Stock Shot Nearly 5% Higher Today
11:35pm, Wednesday, 27'th Apr 2022 The Motley Fool
The company gets a glowing green light from a foreign regulator for one of its pipeline drugs.
Why BioCryst Stock Shot Nearly 5% Higher Today
07:35pm, Wednesday, 27'th Apr 2022
The company gets a glowing green light from a foreign regulator for one of its pipeline drugs.
BioCryst to Report First Quarter 2022 Financial Results on May 5
11:00am, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results T
